S&P TSX Capped Composite...

US Dollar vs CAD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

RAPP Rapport Therapeutics Inc

8.95

-0.01 (-0.11%)

Pre Market

Last Updated: 06:00:08

Delayed by 15 minutes

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Article too big to display. Click here to view on the SEC website

Rapport Therapeutics (NASDAQ:RAPP)
Historical Stock Chart
From Feb 2025 to Mar 2025

Click Here for more Rapport Therapeutics Charts.

Rapport Therapeutics (NASDAQ:RAPP)
Historical Stock Chart
From Mar 2024 to Mar 2025

Click Here for more Rapport Therapeutics Charts.

Rapport Therapeutics Inc News

Form S-8 - Securities to be offered to employees in employee benefit plans
Tuesday 11 March 2025 (1 day ago) • Edgar (US Regulatory)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Tuesday 11 March 2025 (1 day ago) • Edgar (US Regulatory)

Form 8-K - Current report
Tuesday 11 March 2025 (1 day ago) • Edgar (US Regulatory)

Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Tuesday 11 March 2025 (1 day ago) • GlobeNewswire Inc.

Form 8-K - Current report
Monday 3 March 2025 (1 week ago) • Edgar (US Regulatory)

Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development
Monday 3 March 2025 (1 week ago) • GlobeNewswire Inc.

Rapport Therapeutics to Participate in Upcoming Investor Conferences
Monday 24 February 2025 (2 weeks ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 4 February 2025 (1 month ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 4 February 2025 (1 month ago) • Edgar (US Regulatory)

Form 8-K - Current report
Friday 10 January 2025 (2 months ago) • Edgar (US Regulatory)

CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders
Thursday 9 January 2025 (2 months ago) • GlobeNewswire Inc.

Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders
Thursday 9 January 2025 (2 months ago) • GlobeNewswire Inc.

More Rapport Therapeutics Inc News Articles

Jaguar Financial

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions